1. Home
  2. AKBA vs SPT Comparison

AKBA vs SPT Comparison

Compare AKBA & SPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

HOLD

Current Price

$1.60

Market Cap

729.1M

Sector

Health Care

ML Signal

HOLD

SPT

Sprout Social Inc

HOLD

Current Price

$11.42

Market Cap

633.9M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
AKBA
SPT
Founded
2007
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
729.1M
633.9M
IPO Year
2014
2019

Fundamental Metrics

Financial Performance
Metric
AKBA
SPT
Price
$1.60
$11.42
Analyst Decision
Strong Buy
Buy
Analyst Count
6
10
Target Price
$6.25
$26.00
AVG Volume (30 Days)
2.9M
983.9K
Earning Date
11-10-2025
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$225,071,000.00
$443,750,000.00
Revenue This Year
$52.38
$13.30
Revenue Next Year
$22.45
$11.37
P/E Ratio
N/A
N/A
Revenue Growth
32.49
13.09
52 Week Low
$1.45
$9.16
52 Week High
$4.08
$35.18

Technical Indicators

Market Signals
Indicator
AKBA
SPT
Relative Strength Index (RSI) 41.83 58.18
Support Level $1.58 $10.97
Resistance Level $1.71 $11.63
Average True Range (ATR) 0.07 0.44
MACD 0.02 0.03
Stochastic Oscillator 16.67 58.12

Price Performance

Historical Comparison
AKBA
SPT

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

About SPT Sprout Social Inc

Sprout Social Inc develops a cloud software that brings together social messaging, data and workflows in a unified system of record, intelligence, and action. It has a centralized, secure and powerful platform that can scale horizontally across an organization to drive maximum business value. The firm generates majority revenue from software subscriptions.

Share on Social Networks: